Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA increased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 37.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 323,900 shares of the medical equipment provider’s stock after purchasing an additional 87,412 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Lantheus were worth $28,976,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of LNTH. HighTower Advisors LLC acquired a new stake in shares of Lantheus during the third quarter worth about $607,000. Orion Portfolio Solutions LLC lifted its position in Lantheus by 17.2% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 10,291 shares of the medical equipment provider’s stock worth $1,129,000 after acquiring an additional 1,508 shares during the period. MML Investors Services LLC grew its stake in shares of Lantheus by 24.6% in the 3rd quarter. MML Investors Services LLC now owns 4,338 shares of the medical equipment provider’s stock valued at $476,000 after purchasing an additional 857 shares during the last quarter. Groupama Asset Managment acquired a new position in shares of Lantheus in the third quarter valued at approximately $439,000. Finally, M&T Bank Corp raised its stake in shares of Lantheus by 40.4% during the third quarter. M&T Bank Corp now owns 6,847 shares of the medical equipment provider’s stock worth $752,000 after purchasing an additional 1,969 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock worth $6,110,806 in the last three months. Corporate insiders own 2.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on LNTH shares. The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. Truist Financial boosted their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. B. Riley reduced their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Finally, JMP Securities reiterated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and an average price target of $129.43.

Lantheus Trading Down 6.5 %

Shares of Lantheus stock opened at $90.92 on Monday. The company has a 50-day moving average of $93.31 and a two-hundred day moving average of $96.03. The stock has a market cap of $6.23 billion, a PE ratio of 15.13 and a beta of 0.38. Lantheus Holdings, Inc. has a 12-month low of $58.46 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.